Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Lublin
Clinical trial register · Poland

Clinical Trials in Lublin, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Poland and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2705 matching records held by the registry are in this view. Synced 28 Oct 2026, 03:18 UTC
2705
Studies in scope
all four open statuses
1389
Recruiting now
open to new participants
512
Lead sponsors
across recruiting studies
Top sites
Warsaw 1315 Krakow 882 Poznan 705 Gdansk 657 Lodz 619
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca44 Janssen Research & Development, LLC36 Hoffmann-La Roche30 Novo Nordisk A/S18 Merck Sharp & Dohme LLC16
Site location
Warsaw1315 Krakow882 Poznan705 Gdansk657 Lodz619
All 264 locations
Target enrolment
to

Trials with a site in Lublin

523 of 2705 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Poland
Start
Recruiting
Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease
NCT07473700Hypertension, Pulmonary, Lung Diseases, Interstitial
Tectonic Operating Company, Inc.
Phase 2
25
Krakow, Lublin, Wroclaw
2026-10-30
Not yet open
Wockhardt
Phase 3
324
Lublin, Opole, Krakow, Zabrze
2026-10-28
Not yet open
Novo Nordisk A/S
Phase 3
8,500
Lublin, Gorzów Wielkopolski, Grodzisk Mazowiecki, Ostrów Mazowiecka, Warsaw, Bialystok, Częstochowa, Bielsko-Biala
2026-10-26
Not yet open
RBD1119 in Coronary Artery Disease (CAD)
NCT07884136Stable Coronary Artery Disease
DrugRBD1119
Ribocure Pharmaceuticals AB
Phase 2
200
Gdynia, Grodzisk Mazowiecki, Krakow, Lubin, Lublin, Warsaw, Zamość
2026-10-16
Not yet open
Bristol-Myers Squibb
Phase 3
176
Poznan, Wroclaw, Warsaw, Gdansk, Szczecin, Katowice, Lublin, Zabrze
2026-10-02
Recruiting
AstraZeneca
Phase 3
750
Gdansk, Gliwice, Kielce, Krakow, Lublin, Wroclaw
2026-09-24
Recruiting
Janssen Research & Development, LLC
Phase 3
1,000
Katowice, Lublin
2026-09-09
Recruiting
Incyte Corporation
Phase 3
426
Gdansk, Katowice, Krakow, Lodz, Lublin, Warsaw, Wałbrzych
2026-09-08
Recruiting
Bayer
Phase 2
360
Chrzanów, Lublin, Grodzisk Mazowiecki, Bielsko-Biala
2026-09-01
Recruiting
A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07845487Ulcerative Colitis (UC), Severe Ulcerative Colitis, Moderate Ulcerative Colitis
DrugPALI-2108
Palisade Bio
Phase 2
204
Bydgoszcz, Elblag, Katowice, Kielce, Krakow, Kłodzko, Lodz, Lublin
2026-08-28
Recruiting
Novo Nordisk A/S
Phase 3
1,778
Lublin, Bialystok, Chorzów, Bolesławiec, Katowice, Libiąż, Lodz, Olsztyn
2026-08-24
Recruiting
AstraZeneca
Phase 3
7,000
Będzin, Bialystok, Czeladź, Gmina Świecie, Katowice, Kwidzyn, Lodz, Lublin
2026-08-21
Recruiting
Takeda
Observational
110
Poznan, Bydgoszcz, Krakow, Lublin, Warsaw, Opole, Przemyśl, Bialystok
2026-08-13
Recruiting
AstraZeneca
Phase 3
600
Częstochowa, Gdynia, Katowice, Lodz, Lublin, Warsaw
2026-08-12
Recruiting
Novartis Pharmaceuticals
Phase 3
188
Tarnów, Bialystok, Krakow, Lublin, Piaseczno, Torun
2026-08-04
Recruiting
VectivBio AG
Phase 3
124
Bydgoszcz, Lublin, Wroclaw
2026-08
Recruiting
Guerbet
Phase 3
315
Bydgoszcz, Gdansk, Lublin
2026-07-28
Recruiting
AstraZeneca
Phase 3
2,000
Bialystok, Częstochowa, Kielce, Lodz, Lublin, Poznan, Radom, Warsaw
2026-07-06
Recruiting
AstraZeneca
Phase 3
1,200
Bialystok, Krakow, Lodz, Lublin, Poznan, Radom, Warsaw
2026-07-06
Not yet open
Poznan University of Medical Sciences
Not applicable
120
Lublin, Poznan
2026-07-01
Recruiting
Hoffmann-La Roche
Phase 1
25
Bydgoszcz, Lodz, Lublin, Nowy Targ, Pabianice, Późna, Warsaw, Wroc?aw
2026-06-29
Recruiting
AstraZeneca
Phase 3
4,500
Bialystok, Bydgoszcz, Kielce, Krakow, Lodz, Lublin, Poznan, Radom
2026-06-29
Recruiting
AstraZeneca
Phase 3
750
Gdansk, Gliwice, Kielce, Lublin, Poznan, Wroclaw
2026-06-26
Recruiting
Novo Nordisk A/S
Phase 2
300
Lublin, Bialystok, Kielce, Oświęcim
2026-06-22
Recruiting
AstraZeneca
Phase 3
150
Gdansk, Konin, Krakow, Lodz, Lublin, Poznan, Przemyśl, Wroclaw
2026-06-15
Recruiting
Pfizer
Phase 3
954
Bialystok, Gdansk, Lublin, Poznan, Wroclaw
2026-06-10
Recruiting
argenx
Phase 3
230
Krakow, Katowice, Bydgoszcz, Chrzanów, Lublin, Warsaw, Zamość
2026-06-10
Recruiting
Hyaluronic Acid Versus Platelet-Rich Plasma for Chronic Tendinopathy and Enthesopathy
NCT07714811Tendinopathy, Enthesopathy, Achilles Tendinopathy, Golfer's Elbow
Ortonika Orthopedic Medical Clinic in Lublin
Not applicable
80
Lublin
2026-06-10
Recruiting
Panuri Performance Study
NCT07587866Pancreatic Ductal Adenocarcinoma (PDAC)
Urteste S.A
Observational
1,100
Dąbrowa Tarnowska, Gdansk, Grudziądz, Iława, Krakow, Lodz, Lublin, Malbork
2026-06-10
Recruiting
AstraZeneca
Phase 2
80
Bydgoszcz, Krakow, Lodz, Lublin, Warsaw
2026-06-04
Recruiting
Hoffmann-La Roche
Phase 2
120
Warsaw, Bytom, Elblag, Lublin, Nowa Sól, Wroclaw
2026-06-03
Recruiting
Dompé Farmaceutici S.p.A
Phase 3
150
Lublin, Warsaw, Katowice
2026-06-02
Recruiting
Prevention With Ismigen of RTIs in Kids
NCT07578012Respiratory Tract Infections (RTI), Healthy Children
Lallemand Pharma AG
Phase 4
224
Bialystok, Bydgoszcz, Krakow, Lublin, Oświęcim, Poznan, Tarnów
2026-06-01
Recruiting
Janssen Research & Development, LLC
Phase 3
700
Bydgoszcz, Gdansk, Katowice, Lublin, Warsaw, Wałbrzych
2026-05-31
Recruiting
A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
NCT07599813Atopic Dermatitis, Atopic, Dermatitis, Dermatitis, Atopic
Apollo Therapeutics Ltd
Phase 2
280
Bydgoszcz, Chojnice, Gdansk, Katowice, Kielce, Lublin, Piotrkow Trybunalski, Poznan
2026-05-28
Recruiting
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT07357727Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)
DrugsPelabresib·Ruxolitinib
Novartis Pharmaceuticals
Phase 3
460
Gdansk, Katowice, Lublin, Skorzewo, Torun, Warsaw, Wałbrzych
2026-05-27
Recruiting
UCB Biopharma SRL
Phase 3
120
Krakow, Lublin
2026-05-27
Recruiting
Janssen Research & Development, LLC
Phase 3
644
Bydgoszcz, Krakow, Lublin, Olsztyn, Opole, Rzeszów, Szczecin, Torun
2026-05-23
Recruiting
Janssen Research & Development, LLC
Phase 3
460
Bydgoszcz, Krakow, Lublin, Olsztyn, Opole, Rzeszów, Szczecin, Torun
2026-05-22
Not yet open
Novo Nordisk A/S
Phase 3
1,000
Lublin, Grudziądz, Bialystok, Elblag, Gorzów Wielkopolski, Kalwaria Zebrzydowska, Krakow, Legnica
2026-05-20
Recruiting
Ipsen
Phase 3
350
Lublin, Mysłowice, Warsaw
2026-05-14
Recruiting
Novo Nordisk A/S
Phase 3
5,610
Leszno, Chrzanów, Tarnów, Lublin, Płock, Gdynia, Ustroń, Szczecin
2026-05-11
Recruiting
AstraZeneca
Observational
2,150
Lublin, Krakow, Radom, Bialystok, Częstochowa, Poznan, Warsaw, Lodz
2026-05-06
Recruiting
Eli Lilly and Company
Phase 2
60
Katowice, Krakow, Lublin, Poznan, Siedlce, Szczecin, Warsaw, Zamość
2026-05-04
Recruiting
Eli Lilly and Company
Phase 2
60
Katowice, Krakow, Lublin, Poznan, Siedlce, Szczecin, Warsaw, Zamość
2026-05-04
Active, closed
Merck Sharp & Dohme LLC
Phase 2
140
Bydgoszcz, Torun, Lublin, Warsaw
2026-04-20
Recruiting
Effects of Probiotic Supplementation on Stress and Anxiety in Students
NCT07470645Stress, Anxiety, Sleep, Gastro-intestinal Symptoms in Healthy Subjects
Nordic Biotic Sp. z o.o.
Not applicable
200
Lublin
2026-04-20
Recruiting
Novo Nordisk A/S
Phase 2
270
Bialystok, Lublin, Oświęcim, Warsaw, Zabrze
2026-04-17
Recruiting
Visugromab in Cachexia International Trial
NCT07112196Cancer-associated Cachexia
DrugsVisugromab·Visugromab RDE
CatalYm GmbH
Phase 2/3
518
Katowice, Krakow, Lodz, Lublin, Warsaw, Wroclaw
2026-04-16
Recruiting
AstraZeneca
Phase 3
245
Bydgoszcz, Częstochowa, Katowice, Krakow, Lodz, Lublin, Nadarzyn, Nowa Sól
2026-04-13
Recruiting
Boehringer Ingelheim
Phase 3
670
Gdansk, Lodz, Lublin, Olsztyn
2026-04-13
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
400
Poznan, Wroclaw, Warsaw, Gdansk, Szczecin, Katowice, Lublin, Zabrze
2026-04-07
Recruiting
Hoffmann-La Roche
Phase 2
80
?ód?, Bialystok, Lublin, Wroc?aw
2026-04-07
Recruiting
Michał Pasierbek
Not applicable
120
Wroclaw, Lublin, Warsaw, Krakow, Gdansk, Zabrze, Olsztyn, Kielce
2026-04-01
Recruiting
AstraZeneca
Phase 1
40
Brzozów, Koszalin, Lublin, Olsztyn, Przemyśl
2026-03-31
Recruiting
Yuhan Corporation
Phase 2
150
Poznan, Krakow, Tarnów, Wroclaw, Lublin, Opole, Bialystok, Katowice
2026-03-26
Recruiting
Zenas BioPharma (USA), LLC
Phase 3
705
Bydgoszcz, Zabrze, Katowice, Plewiska, Poznan, Gdansk, Lublin, Nowa Sól
2026-03-23
Recruiting
Zenas BioPharma (USA), LLC
Phase 3
990
Bydgoszcz, Nowa Sól, Rzeszów, Katowice, Poznan, Lodz, Lublin, Szczecin
2026-03-23
Recruiting
Hoffmann-La Roche
Phase 3
1,600
Bialystok, Bydgoszcz, Dębica, Lublin, Pabianice, Poznan, Ruda Śląska, Siedlce
2026-03-23
Recruiting
Hoffmann-La Roche
Phase 3
2,000
Bialystok, Bydgoszcz, Gdynia, Krakow, Lublin, Opole, Tarnów, Tychy
2026-03-16
Recruiting
Bristol-Myers Squibb
Phase 3
850
Lublin, Opole, Przemyśl, Katowice
2026-03-16
Recruiting
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
NCT07332481Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)
DrugEnpatoran
EMD Serono Research & Development Institute, Inc.
Phase 3
202
Krakow, Lublin, Malbork, Rzeszów, Warsaw, Zamość
2026-03-10
Recruiting
AstraZeneca
Phase 3
508
Gdansk, Gliwice, Lublin, Poznan, Warsaw, Wroclaw
2026-02-23
Active, closed
EyePoint Pharmaceuticals, Inc.
Phase 3
240
Bydgoszcz, Lublin, Olsztyn, Tarnów, Warsaw
2026-02-16
Active, closed
Janssen Research & Development, LLC
Phase 2
168
Brzozów, Kielce, Krakow, Lodz, Lublin, Poznan, Torun, Wroclaw
2026-02-08
Recruiting
Eli Lilly and Company
Phase 3
1,980
Bialystok, Krakow, Lodz, Lublin, Poznan, Wroclaw, Zabrze
2026-02-06
Recruiting
AstraZeneca
Phase 3
2,130
Gdansk, Koszalin, Krakow, Lublin, Olsztyn, Warsaw
2026-02-03
Recruiting
Exciva GmbH
Phase 2/3
300
Poznan, Krakow, Wroclaw, Lublin, Sochaczew, Warsaw, Katowice, Zabrze
2026-02-02
Not yet open
Undiluted and Diluted Nutrition
NCT07352150Critical Illness, Gastro Intestinal Surgery, Enteral Feeding Intolerance, Gastro-Intestinal Disorder
John Paul II Catholic University of Lublin
Not applicable
80
Lublin
2026-02-02
By invitation
Immunovant Sciences GmbH
Phase 2
372
Bydgoszcz, Lublin, Warsaw, Kielce
2026-01-26
Recruiting
Sanofi
Phase 3
751
Bydgoszcz, Elblag, Katowice, Kłodzko, Lublin, Rzeszów, Staszów, Szczecin
2026-01-22
Recruiting
BeOne Medicines
Phase 3
500
Brzozów, Katowice, Krakow, Lublin, Wroclaw
2026-01-22
Recruiting
Sanofi
Phase 3
751
Bydgoszcz, Elblag, Katowice, Krakow, Kłodzko, Lublin, Opole, Poznan
2026-01-16
Recruiting
Celldex Therapeutics
Phase 3
240
Gdansk, Krakow, Lodz, Lublin, Opole, Oświęcim, Rzeszów, Tarnów
2026-01-15
Recruiting
Janssen Research & Development, LLC
Phase 2
240
Bialystok, Bydgoszcz, Elblag, Krakow, Lublin, Nadarzyn, Olsztyn, Torun
2026-01-15
Active, closed
Kailera
Phase 3
1,270
Bydgoszcz, Torun, Krakow, Lublin, Siedlce, Warsaw, Bialystok, Gdynia
2026-01-12
Recruiting
Insmed Incorporated
Phase 3
344
Bialystok, Krakow, Lublin, Warsaw
2026-01-07
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
DrugsPF-08634404·Pembrolizumab
Pfizer
Phase 3
1,410
Radom, Katowice, Kielce, Lodz, Lublin, Opole, Wroclaw, Tomaszów Mazowiecki
2026-01-06
Recruiting
Eli Lilly and Company
Phase 3
1,035
Bialystok, Bydgoszcz, Elblag, Krakow, Lodz, Lublin, Ruda Śląska, Zabrze
2025-12-15
Recruiting
UCB Biopharma SRL
Phase 1
392
Bialystok, Bytom, Elblag, Krakow, Lodz, Lublin, Nowa Sól, Olsztyn
2025-12-10
Recruiting
AstraZeneca
Phase 2
230
Lublin, Warsaw
2025-12-10
Recruiting
Hoffmann-La Roche
Phase 2
160
Bytom, Elbl?g, Krakow, Lublin, Nowa Sól, Warsaw, Wroclaw
2025-12-05
Recruiting
Takeda
Phase 3
110
Wroclaw, Lublin, Rzeszów, Gdansk, Lodz
2025-12-04
Recruiting
Janssen Research & Development, LLC
Phase 3
500
Gdansk, Gliwice, Lodz, Lublin, Poznan, Warsaw
2025-12-03
Recruiting
Bristol-Myers Squibb
Phase 3
366
Lublin, Warsaw, Bialystok, Gdansk, Lodz, Olsztyn
2025-12-03
Recruiting
Bristol-Myers Squibb
Phase 3
650
Poznan, Bydgoszcz, Chorzów, Katowice, Krakow, Lublin, Sochaczew, Wroclaw
2025-12-02
Recruiting
Pfizer
Phase 3
450
Lublin, Warsaw, Chorzów, Katowice, Lodz, Ostrowiec Świętokrzyski
2025-12-02
Recruiting
Eli Lilly and Company
Phase 3
7,140
Bialystok, Bydgoszcz, Elblag, Krakow, Lodz, Lublin, Radom, Ruda Śląska
2025-12-01
Recruiting
Genmab
Phase 3
660
Lublin, Siedlce, Bialystok, Szczecin, Kielce, Lodz
2025-11-28
Recruiting
Hoffmann-La Roche
Phase 3
250
Krakow, Bielsko-Biala, Bydgoszcz, Gliwice, Lódz, Lublin, Olsztyn
2025-11-27
Recruiting
AbbVie
Phase 2
180
Poznan, Lublin, Warsaw
2025-11-25
By invitation
Celldex Therapeutics
Phase 3
1,370
Bialystok, Częstochowa, Elblag, Gdansk, Katowice, Krakow, Lublin, Oświęcim
2025-11-25
Recruiting
Hoffmann-La Roche
Phase 3
900
Bia?ystok, Bydgoszcz, Gda?sk, Katowice, Krakow, Lublin, Oświęcim, Rzeszów
2025-11-24
Active, closed
Kymera Therapeutics, Inc.
Phase 2
200
Chorzów, Gdansk, Gdynia, Krakow, Lublin, Rzeszów, Szczecin, Warsaw
2025-11-24
Active, closed
Qilu Pharmaceutical Co., Ltd.
Phase 3
146
Olsztyn, Lublin
2025-11-21
Recruiting
Incyte Corporation
Phase 3
250
Gdansk, Katowice, Krakow, Lublin, Nowa Sól, Osielsko, Rzeszów, Szczecin
2025-11-13
Recruiting
AstraZeneca
Phase 3
420
Kielce, Krakow, Lodz, Lublin, Wroclaw
2025-11-11
Recruiting
Novartis Pharmaceuticals
Phase 3
1,275
Krakow, Bydgoszcz, Chojnice, Katowice, Lodz, Lublin, Rzeszów, Skorzewo
2025-11-11
Active, closed
Novo Nordisk A/S
Phase 3
300
Bialystok, Katowice, Lublin, Warsaw
2025-11-05
Recruiting
Bristol-Myers Squibb
Phase 2/3
500
Poznan, Lublin, Bydgoszcz
2025-11-05
Active, closed
Bluefin Biomedicine, Inc.
Phase 2/3
210
Bialystok, Lublin, Wroclaw
2025-11-03
Recruiting
Pfizer
Phase 2
200
Warsaw, Chorzów, Gdansk, Lublin, Tarnów, Wroclaw
2025-10-30
Recruiting
BioNTech SE
Phase 3
558
Gdansk, Krakow, Lodz, Lublin, Poznan, Warsaw
2025-10-30
By invitation
Clinical Trial of Vormatrigine in Adult Patients With Epilepsy
NCT07287163Epilepsy, Tonic-Clonic, Focal Seizure, Primary Generalized Seizure
Praxis Precision Medicines
Phase 3
700
Bydgoszcz, Katowice, Lublin, Warsaw
2025-10-27
Recruiting
Hoffmann-La Roche
Phase 3
600
Bystra, Gda?sk, Krakow, Lublin, Olsztyn, Poznan, Radom, Warsaw
2025-10-24
Recruiting
Novo Nordisk A/S
Phase 1
30
Bialystok, Gdansk, Katowice, Lublin, Poznan, Warsaw
2025-10-23
Recruiting
A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)
NCT07194850Immune Thrombocytopenia (ITP), ITP - Immune Thrombocytopenia, ITP, Immune Thrombocytopenic Purpura
DrugEfgartigimod
argenx
Phase 2/3
24
Lodz, Lublin
2025-10-20
Active, closed
Gesynta Pharma AB
Phase 2
213
Bialystok, Bydgoszcz, Katowice, Krakow, Lublin, Siedlce, Skorzewo, Szczecin
2025-10-15
By invitation
Updated Abdominal Compartment Society Consensus Definitions
NCT07563842Abdominal Hypertension, Abdominal Compartment Syndrome
Medical University of Lublin
Observational
60
Lublin
2025-10-13
Active, closed
Merck Sharp & Dohme LLC
Phase 2
185
Bydgoszcz, Torun, Lublin, Warsaw, Bytom
2025-10-08
Recruiting
Janssen Research & Development, LLC
Phase 2/3
1,092
Bydgoszcz, Krakow, Lublin, Nowy Targ, Olsztyn, Opole, Poznan, Rzeszów
2025-10-03
Recruiting
Janssen Research & Development, LLC
Phase 3
882
Bydgoszcz, Katowice, Krakow, Lublin, Nowy Targ, Olsztyn, Opole, Poznan
2025-10-01
Active, closed
A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in Europe (PLATINUM EU)
NCT07210463Neuromuscular Agents, Peripheral Nervous System Agents, Physiological Effects of Drugs, Acetylcholine Release Inhibitors
DrugXeomin
Merz Aesthetics GmbH
Phase 3
300
Krakow, Oświęcim, Lublin, Warsaw, Bialystok, Gdynia, Lodz, Ostrowiec Świętokrzyski
2025-10-01
Recruiting
Sanofi
Phase 3
980
Bydgoszcz, Elblag, Katowice, Krakow, Kłodzko, Lodz, Lublin, Nowy Targ
2025-10-01
Recruiting
Pfizer
Phase 3
680
Lublin, Poznan, Tomaszów Mazowiecki, Lodz
2025-09-29
Recruiting
Pfizer
Phase 3
1,000
Poznan, Wroclaw, Szczecin, Koszalin, Krakow, Lublin, Rzeszów
2025-09-28
Recruiting
Merck Sharp & Dohme LLC
Phase 2
315
Bydgoszcz, Torun, Lublin, Warsaw
2025-09-26
Recruiting
Lohmann & Rauscher
Not applicable
150
Bialystok, Krakow, Lodz, Lublin, Ostróda, Wroclaw, Zabrze
2025-09-23
Recruiting
Bristol-Myers Squibb
Phase 3
3,040
Poznan, Torun, Wroclaw, Lublin, Puławy, Warsaw, Rzeszów, Bialystok
2025-09-22
Active, closed
Hoffmann-La Roche
Phase 3
1,101
Bydgoszcz, Katowice, Krakow, Lublin, Rzeszów, Warsaw, Wroc?aw, Zabrze
2025-09-17
Recruiting
LEO Pharma
Phase 2
135
Bialystok, Iwonicz-Zdrój, Lodz, Lublin, Rzeszów, Warsaw, Wroclaw
2025-09-11
Recruiting
Pfizer
Phase 3
140
Krakow, Wroclaw, Lublin, Warsaw, Katowice, Rzeszów, Lodz
2025-09-10
Recruiting
BeOne Medicines
Phase 3
500
Gdansk, Kielce, Lodz, Lublin, Olsztyn, Torun, Warsaw, Wroclaw
2025-09-04
Recruiting
Relay Therapeutics, Inc.
Phase 3
540
Konin, Krakow, Lublin, Poznan, Rzeszów, Warsaw
2025-08-26
Recruiting
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
NCT06920004Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
DrugsEmpasiprubart·IVIG
argenx
Phase 3
218
Bydgoszcz, Katowice, Krakow, Lublin, Poznan, Rzeszów, Szczecin, Warsaw
2025-08-22
Active, closed
Merz Therapeutics GmbH
Phase 3
808
Bydgoszcz, Dębica, Gdynia, Katowice, Krakow, Lublin, Oświęcim, Poznan
2025-08-21
Active, closed
Merz Therapeutics GmbH
Phase 3
997
Bydgoszcz, Dębica, Gdynia, Katowice, Krakow, Lublin, Oświęcim, Poznan
2025-08-21
Active, closed
Hoffmann-La Roche
Phase 2
330
Bialystok, Gdansk, Bydgoszcz, Katowice, Lublin, Tarnów, Warsaw, Wroclaw
2025-08-19
Active, closed
Novo Nordisk A/S
Phase 3
877
Krakow, Oświęcim, Tarnów, Legnica, Bydgoszcz, Gdansk, Lodz, Lublin
2025-08-11
Recruiting
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
NCT06774131Upper Urinary Tract Urothelial Carcinoma, Urothelial Carcinoma
UroGen Pharma Ltd.
Phase 3
70
Opole, Gdansk, Bydgoszcz, Katowice, Lublin, Olsztyn, Szczecin, Wroclaw
2025-08-06
Recruiting
Sanofi
Phase 3
723
Lublin, Lodz, Warsaw, Bialystok
2025-08-06
Recruiting
CatalYm GmbH
Phase 2
107
Lublin, Poznan, Prabuty
2025-08-01
Recruiting
DCB vs. DES in Bifurcation Coronary Lesions
NCT06551662Coronary Artery Disease, DCB
Fondazione Ricerca e Innovazione Cardiovascolare ETS
Not applicable
321
Gdansk, Katowice, Krakow, Lubin, Lublin, Poznan, Rzeszów, Warsaw
2025-08-01
Active, closed
Pfizer
Phase 3
208
Krakow, Wroclaw, Lublin, Warsaw, Bialystok, Katowice, Ossy, Rzeszów
2025-07-31
Recruiting
Antegrade Dissection and Re-entry Versus Retrograde Strategy in CTO PCI
NCT06878729Coronary Artery Disease, Coronary Occlusion, Percutaneous Coronary Intervention
National Institute of Cardiology, Warsaw, Poland
Not applicable
74
Warsaw, Lublin
2025-07-28
Recruiting
EAST-1 (ERAP-inhibition in Axial Spondyloarthritis Trial - 1)
NCT07047703Axial Spondyloarthritis (AxSpA)
Grey Wolf Therapeutics
Phase 1/2
140
Krakow, Lublin, Poznan
2025-07-28
Recruiting
Pfizer
Phase 3
150
Krakow, Lublin, Warsaw, Chorzów, Katowice, Lodz, Ostrowiec Świętokrzyski
2025-07-24
Recruiting
AbbVie
Phase 1/2
325
Poznan, Lublin, Warsaw
2025-07-23
Recruiting
Pfizer
Phase 3
714
Poznan, Lublin, Warsaw, Gdansk, Gliwice, Lodz
2025-07-23
Recruiting
Bristol-Myers Squibb
Phase 3
586
Oświęcim, Wroclaw, Lublin, Katowice
2025-07-21
Recruiting
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
NCT06765109Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive
DrugsNeladalkib·Alectinib
Nuvalent Inc.
Phase 3
450
Brzozów, Gdansk, Lublin, Szczecin
2025-07-17
Recruiting
Bristol-Myers Squibb
Phase 3
426
Poznan, Bydgoszcz, Chorzów, Katowice, Krakow, Lublin, Sochaczew, Wroclaw
2025-07-16
Recruiting
Hoffmann-La Roche
Observational
700
Krakow, Lublin, Olsztyn, Poznan, Słupsk, Tomaszów Mazowiecki
2025-07-15
Recruiting
Helsinn Healthcare SA
Phase 2
95
Bialystok, Bydgoszcz, Lodz, Lublin, Olsztyn, Poznan, Szczecin, Warsaw
2025-07-07
Active, closed
Upstream Bio Inc.
Phase 2
666
Bydgoszcz, Poznan, Krakow, Lublin, Nowa Sól, Skierniewice, Sochaczew, Rzeszów
2025-07-02
Recruiting
Novo Nordisk A/S
Phase 2
200
Wroclaw, Lublin, Bialystok, Biała Podlaska, Bielsko-Biala, Krakow, Przemyśl, Warsaw
2025-06-30
Active, closed
Immunovant Sciences GmbH
Phase 2
180
Bydgoszcz, Krakow, Lodz, Lublin, Poznan, Siedlce, Warsaw, Wołomin
2025-06-30
Recruiting
Novo Nordisk A/S
Phase 2
200
Wroclaw, Lublin, Bialystok, Szczecin, Bielsko-Biala, Krakow, Lodz, Przemyśl
2025-06-27
By invitation
MoonLake Immunotherapeutics AG
Phase 3
835
Bialystok, Chorzów, Gdansk, Katowice, Kielce, Krakow, Lodz, Lublin
2025-06-27
Recruiting
Eli Lilly and Company
Phase 3
290
Lublin, Opole, Piotrkow Trybunalski, Poznan, Rzeszów, Szczecin, Warsaw, Wroclaw
2025-06-26
Recruiting
Immunovant Sciences GmbH
Phase 2
210
Bialystok, Szczecin, Bydgoszcz, Chorzów, Kielce, Lublin, Olsztyn, Opole
2025-06-19
Active, closed
Incyte Corporation
Phase 3
159
Gdansk, Katowice, Krakow, Lodz, Lublin, Szczecin, Torun, Warsaw
2025-06-17
Active, closed
Incyte Corporation
Phase 3
573
Lublin, Poznan, Rzeszów, Wroclaw
2025-06-12
Active, closed
Sandoz
Phase 3
183
Bydgoszcz, Katowice, Lodz, Lublin, Nowa Sól, Poznan, Szczecin, Warsaw
2025-06-10
Recruiting
Sanofi
Phase 2
99
Wroclaw, Krakow, Lublin, Sopot, Warsaw
2025-06-03
Active, closed
C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV
NCT07037277HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic, Hepatitis C Virus Infection, Hepatitis C
DrugsBemnifosbuvir-Ruzasvir·Sofosbuvir-Velpatasvir
Atea Pharmaceuticals, Inc.
Phase 3
880
Krakow, Kłodzko, Lublin, Mysłowice, Warsaw, Wroclaw
2025-06-02
Recruiting
MediWound Ltd
Phase 3
216
Krakow, Lublin, Warsaw, Bialystok, Siemianowice Śląskie, Tychy, Lodz, Nowy Targ
2025-06-01
Active, closed
AstraZeneca
Phase 3
3,103
Bialystok, Gdansk, Gdynia, Katowice, Kędzierzyn-Koźle, Krakow, Lodz, Lublin
2025-05-28
Recruiting
Takeda
Phase 2
192
Torun, Lublin, Szczecin, Warsaw
2025-05-28
Recruiting
Immunovant Sciences GmbH
Phase 3
231
Gdansk, Katowice, Krakow, Lublin, Warsaw
2025-05-27
Recruiting
Polish Registry of Percutaneous Coronary Intervention for Chronic Total Occlusions
NCT07330622Coronary Occlusion, Percutaneous Coronary Intervention
National Institute of Cardiology, Warsaw, Poland
Observational
1,000
Bialystok, Grodzisk Mazowiecki, Inowrocław, Katowice, Krakow, Lubin, Lublin, Nowy Sącz
2025-05-21
Recruiting
Boehringer Ingelheim
Phase 3
4,200
Bielsko-Biala, Bydgoszcz, Gdynia, Krakow, Legnica, Lodz, Lublin, Piaseczno
2025-05-20
Recruiting
Novartis Pharmaceuticals
Phase 2
224
Warsaw, Katowice, Lodz, Lublin
2025-05-16
Recruiting
AstraZeneca
Observational
50
Bydgoszcz, Gdansk, Katowice, Krakow, L DZ, Lublin, Poznan, Szczecin
2025-05-15
Recruiting
Apogee Therapeutics, Inc.
Phase 2
350
Wroclaw, Lublin, Warsaw, Gdansk, Katowice, Sosnowiec, Szczecin, Krakow
2025-05-14
Active, closed
Boehringer Ingelheim
Phase 1
91
Lublin
2025-05-14
Recruiting
Hoffmann-La Roche
Phase 3
425
Bia?ystok, Bydgoszcz, Elblag, I?awa, Knurów, Krakow, Lodz, Lublin
2025-05-12
Recruiting
AstraZeneca
Phase 3
1,220
Bydgoszcz, Gdansk, Koszalin, Lublin, Olsztyn, Warsaw
2025-05-06
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma)
DrugsCetuximab·Docetaxel
Revolution Medicines, Inc.
Phase 3
590
Gdansk, Lublin, Poznan, Skorzewo
2025-05-06
Recruiting
Takeda
Phase 3
59
Krakow, Lublin, Warsaw, Gdansk
2025-05-06
Active, closed
Hoffmann-La Roche
Phase 2
285
Krakow, Gdansk, Lublin, Warsaw
2025-05-05
Recruiting
Mirati Therapeutics Inc.
Phase 3
630
Poznan, Gorlice, Krakow, Wroclaw, Lublin, Bydgoszcz, Katowice, Prabuty
2025-04-24
Active, closed
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 2
83
Poznan, Wroclaw, Siedlce, Warsaw, Wołomin, Bydgoszcz, Katowice, Lublin
2025-04-23
Active, closed
Merck Sharp & Dohme LLC
Phase 2
440
Krakow, Lublin, Bialystok
2025-04-16
Recruiting
Hoffmann-La Roche
Not applicable
270
Gdansk, Krakow, Kraśnik, Lublin, Nadarzyn, Warsaw
2025-04-14
Recruiting
BeOne Medicines
Phase 3
250
Brzozów, Katowice, Krakow, Lodz, Lublin, Wroclaw
2025-04-10
Recruiting
Hoffmann-La Roche
Phase 3
450
?ód?, Bialystok, Konin, Koszalin, Krakow, Lublin, Późna, Rzeszów
2025-04-09
By invitation
Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP
NCT06859099Polyneuropathy, Inflammatory Demyelinating, Chronic
DrugRiliprubart
Sanofi
Phase 3
300
Lublin
2025-04-01
Recruiting
Pfizer
Phase 3
674
Poznan, Krakow, Wroclaw, Lublin, Nowa Sól, Warsaw, Katowice, Sosnowiec
2025-04-01
Recruiting
Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
NCT06980116Relapsed or Refractory B-cell Malignancies, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Follicular Lymphoma (FL), Marginal Zone Lymphoma (MZL)
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Phase 1
85
Krakow, Lodz, Lublin, Skórzewo
2025-03-31
Recruiting
Eli Lilly and Company
Phase 2
200
Bialystok, Gdansk, Krakow, Lodz, Lublin, Tarnów, Warsaw, Wroclaw
2025-03-28
Recruiting
Daiichi Sankyo
Phase 3
510
Lublin, Siedlce, Warsaw
2025-03-27
Active, closed
Sun Pharmaceutical Industries Limited
Phase 3
206
Wroclaw, Lublin, Krakow, Rzeszw, Malbork, Bialystok-Podlaskie, Katowice, Warsaw
2025-03-21
Recruiting
Immunovant Sciences GmbH
Phase 2
162
Lublin, Bydgoszcz, Gdansk, Katowice, Krakow, Poznan, Warsaw
2025-03-18
Active, closed
Amgen
Phase 3
1,105
Katowice, Lodz, Lublin, Oświęcim, Puławy, Ruda Śląska, Staszów, Świdnik
2025-03-17
Active, closed
Amgen
Phase 3
3,853
Bialystok, Dębica, Gdynia, Katowice, Lodz, Lublin, Poznan, Warsaw
2025-03-12
Recruiting
Treatment of Presymptomatic (Stage 1) Type 1 Diabetes Pediatric Patients With Treg Cell Preparations and Anti-CD20 Antibody
NCT06688331Presymptomatic Diabetes Type 1 (Stage 1), Diabetes Mellitus, Type I, Diabetes Mellitus, Type 1
DrugRituximab
PolTREG S.A.
Phase 2
150
Bialystok, Gdansk, Katowice, Lodz, Lublin, Opole, Rzeszów, Szczecin
2025-03-12
Recruiting
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3
440
Lublin, Gdansk, Katowice, Lodz
2025-03-12
Recruiting
Pfizer
Phase 3
723
Krakow, Oświęcim, Wroclaw, Lublin, Warsaw, Katowice
2025-03-11
Recruiting
AbbVie
Phase 1/2
252
Lublin, Bialystok, Gdansk, Kielce
2025-03-06
Recruiting
BeOne Medicines
Phase 3
300
Krakow, Lodz, Lublin, Skorzewo, Wroclaw
2025-03-05
Recruiting
AstraZeneca
Phase 3
5,000
Bialystok, Gdynia, Gmina Świecie, Jasło, Katowice, Krakow, Lodz, Lublin
2025-03-03
Active, closed
AstraZeneca
Observational
105
Bydgoszcz, Bytom, Gdansk, Katowice, Krakow, Lodz, Lublin, Poznan
2025-02-28
Recruiting
Summit Therapeutics
Phase 3
780
Gdansk, Lodz, Lublin, Poznan, Skorzewo
2025-02-27
Recruiting
Amgen
Phase 3
844
Poznan, Krakow, Wroclaw, Lublin, Warsaw, Wołomin, Malbork, Bydgoszcz
2025-02-25
Active, closed
Janssen Research & Development, LLC
Phase 3
552
Bialystok, Bydgoszcz, Elblag, Gdynia, Krakow, Lodz, Lublin, Nadarzyn
2025-02-21
Active, closed
Sanofi
Phase 3
231
Krakow, Wroclaw, Lublin, Warsaw, Bialystok
2025-02-12
Recruiting
Dianthus Therapeutics
Phase 3
256
Bydgoszcz, Krakow, Lodz, Lublin, Warsaw, Wroclaw
2025-02-10
Active, closed
Novartis Pharmaceuticals
Phase 3
180
Lublin, Krakow, Bydgoszcz, Katowice, Lodz, Poznan, Skorzewo, Warsaw
2025-02-07
Active, closed
Real-life Treatment Outcomes of Ravulizumab in PNH
NCT06633536Paroxysmal Nocturnal Haemoglobinuria
DrugRavulizumab
AstraZeneca
Observational
64
Bialystok, Brzozów, Bydgoszcz, Gdansk, Krakow, Lodz, Lublin, Opole
2025-02-06
Recruiting
BioNTech SE
Phase 3
621
Gdansk, Katowice, Konin, Koszalin, Krakow, Lodz, Lublin, Olsztyn
2025-02-03
Active, closed
Viridian Therapeutics, Inc.
Phase 3
320
Bialystok, Gdansk, Gdynia, Lodz, Lublin, Piaseczno, Warsaw
2025-02-03
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,046
Wroclaw, Lublin, Warsaw, Słupsk, Gliwice, Katowice, Olsztyn
2025-01-27
Recruiting
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
NCT06680830Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Early Parkinson Disease (Early PD)
Neuron23 Inc.
Phase 2
150
Bydgoszcz, Katowice, Lublin, Warsaw
2025-01-17
Active, closed
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
NCT06700343Relapsing-remitting Multiple Sclerosis (RRMS)
DrugOcrelizumab
Amgen
Phase 3
152
Bydgoszcz, Katowice, Kielce, Krakow, Lodz, Lublin, Poznan, Warsaw
2025-01-13
Active, closed
Immunovant Sciences GmbH
Phase 2
120
Bialystok, Elblag, Lublin, Nadarzyn, Poznan, Sochaczew, Warsaw, Wroclaw
2025-01-10
Recruiting
Janssen Research & Development, LLC
Phase 3
750
Bialystok, Bydgoszcz, Elblag, Gdynia, Krakow, Lodz, Lublin, Nadarzyn
2025-01-09
Not yet open
Diluted and Undiluted Enteral Nutrition
NCT06516835Critical Illness, Surgery, Enteral Feeding Intolerance, Gastro-Intestinal Disorder
Medical University of Lublin
Not applicable
60
Gorzów Wielkopolski, Krakow, Lublin, Opole
2025-01-02
Recruiting
Supernus Pharmaceuticals, Inc.
Phase 2
216
Krakow, Warsaw, Gdynia, Sopot, Katowice, Lublin
2024-12-30
Active, closed
mAbxience Research S.L.
Phase 3
726
Katowice, Lodz, Lublin, Prabuty, Słupsk
2024-12-30
Active, closed
argenx
Phase 3
154
Bydgoszcz, Katowice, Krakow, Lublin, Warsaw
2024-12-18
Recruiting
Immunovant Sciences GmbH
Phase 2
240
Gliwice, Krakow, Lublin, Poznan, Warsaw
2024-12-17
Recruiting
GlaxoSmithKline
Phase 3
520
Lodz, Lublin, Warsaw, Wałbrzych
2024-12-16
Active, closed
Hoffmann-La Roche
Phase 3
350
?ód?, Bydgoszcz, Elblag, I?awa, Knurów, Krakow, Lublin, Poznan
2024-12-11
Recruiting
Boehringer Ingelheim
Phase 2
80
Krakow, Lublin, Pabianice, Poznan, Rzeszów, Sopot, Szczecin, Torun
2024-12-11
Active, closed
Janssen Research & Development, LLC
Phase 3
655
Bydgoszcz, Dębica, Krakow, Lublin, Olsztyn, Poznan, Siedlce, Warsaw
2024-12-04
Recruiting
OSE Immunotherapeutics
Phase 3
363
Konin, Poznan, Bydgoszcz, Lublin, Lodz, Gdansk
2024-12-03
Recruiting
Novo Nordisk A/S
Phase 2
465
Włocławek, Lublin, Rzeszów, Bialystok, Gmina Świecie, Katowice, Lodz, Olsztyn
2024-12-02
Recruiting
BeOne Medicines
Phase 1/2
80
Gdansk, Lublin, Olsztyn, Opole, Warsaw
2024-11-27
Recruiting
AstraZeneca
Phase 3
1,160
Bialystok, Biała Podlaska, Bydgoszcz, Bystra, Lodz, Lublin, Poznan, Warsaw
2024-11-27
Active, closed
EyePoint Pharmaceuticals, Inc.
Phase 3
400
Bydgoszcz, Krakow, Lublin, Olsztyn, Tarnów, Warsaw
2024-11-27
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,380
Poznan, Włocławek, Krakow, Wroclaw, Lublin, Warsaw, Katowice, Szczecin
2024-11-25
Recruiting
Shanghai Henlius Biotech
Phase 3
550
Brzozów, Gdansk, Koszalin, Lodz, Lublin, Otwock, Skorzewo, Słupsk
2024-11-22
Recruiting
UCB Biopharma SRL
Phase 3
450
Katowice, Krakow, Lublin, Poznan, Warsaw, Wroclaw
2024-11-21
Active, closed
Daiichi Sankyo
Phase 3
700
Lublin, Warsaw
2024-11-19
Recruiting
AstraZeneca
Phase 3
1,160
Bialystok, Biała Podlaska, Bydgoszcz, Bystra, Lodz, Lublin, Poznan, Warsaw
2024-11-18
Active, closed
Pfizer
Phase 3
636
Bydgoszcz, Krakow, Wroclaw, Lublin, Warsaw
2024-11-15
Active, closed
BeOne Medicines
Phase 2
94
Katowice, Krakow, Lublin, Wroclaw
2024-11-14
Recruiting
Boehringer Ingelheim
Phase 3
1,590
Krakow, Lodz, Lublin, Mysłowice, Warsaw, Wroclaw
2024-11-12
Active, closed
argenx
Phase 2
87
Krakow, Lublin, Nowa Sól, Warsaw, Wroclaw
2024-11-11
Active, closed
Amgen
Phase 2
409
Bialystok, Krakow, Lublin, Staszów, Warsaw, Wroclaw
2024-11-07
Active, closed
Eli Lilly and Company
Phase 3
800
Poznan, Lublin, Bialystok, Ruda Śląska, Lodz
2024-11-01
Recruiting
Société des Produits Nestlé (SPN)
Not applicable
104
Bialystok, Bydgoszcz, Janki, Krakow, Lodz, Lublin, Rzeszów, Tarnów
2024-10-25
Recruiting
Pfizer
Phase 3
900
Krakow, Wroclaw, Lublin, Warsaw, Koszalin, Opole, Piotrkow Trybunalski
2024-10-22
Recruiting
argenx
Phase 3
69
Bydgoszcz, Katowice, Lodz, Lublin, Nowy Sącz, Torun
2024-10-18
Recruiting
Boehringer Ingelheim
Phase 3
1,800
Krakow, Lodz, Lublin, Mysłowice, Warsaw, Wroclaw
2024-10-14
Active, closed
Incyte Corporation
Phase 3
346
Gdansk, Katowice, Lodz, Lublin, Poznan, Rzeszów, Torun, Warsaw
2024-10-10
Active, closed
Eli Lilly and Company
Phase 2
143
Bydgoszcz, Krakow, Lodz, Lublin, Opole, Poznan, Sopot, Torun
2024-10-10
Active, closed
Incyte Corporation
Phase 3
349
Bialystok, Gdansk, Katowice, Krakow, Lublin, Pruszków, Szczecin, Warsaw
2024-10-10
Recruiting
AbbVie
Phase 2
488
Bydgoszcz, Katowice, Krakow, Lublin, Poznan, Warsaw
2024-10-07
Recruiting
Stemline Therapeutics, Inc.
Phase 3
4,220
Poznan, Wroclaw, Lublin, Otwock, Warsaw, Gdynia, Lodz
2024-09-27
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
406
Poznan, Gdansk, Iława, Kielce, Lodz, Lublin, Sochaczew, Wroclaw
2024-09-26
Active, closed
Cerevance
Phase 3
330
Lublin, Warsaw, Katowice
2024-09-20
Active, closed
argenx
Phase 3
141
Bydgoszcz, Katowice, Krakow, Lublin
2024-09-18
Active, closed
Amgen
Phase 1
49
Gdansk, Gliwice, Krakow, Lodz, Lublin
2024-09-17
Active, closed
Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)
NCT06430866Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)
DrugsABP 234·Pembrolizumab
Amgen
Phase 3
163
Bydgoszcz, Lublin, Olsztyn, Krakow, Przemyśl, Sosnowiec
2024-09-12
Active, closed
Amgen
Phase 3
315
Bydgoszcz, Lublin, Olsztyn, Lodz, Poznan, Słupsk
2024-09-09
Active, closed
Tectonic Therapeutic
Phase 2
191
Bialystok, Krakow, Lodz, Lublin, Warsaw, Wroclaw
2024-09-04
Active, closed
Takeda
Phase 3
2,099
Poznan, Krakow, Katowice, Kłodzko, Wroclaw, Lublin, Lódz, Nadarzyn
2024-09-04
Recruiting
Pomeranian Medical University Szczecin
Observational
300
Bialystok, Gdansk, Gliwice, Kielce, Krakow, Lublin, Opole, Siedlce
2024-09-02
Active, closed
Phase IIa Study Evaluating AZD7798 in Crohn's Disease
NCT06450197Moderate to Severe Crohn's Disease
DrugAZD7798
AstraZeneca
Phase 2
120
Bydgoszcz, Chojnice, Krakow, Lublin, Poznan, Sopot, Warsaw, Wroclaw
2024-08-28
Active, closed
Viridian Therapeutics, Inc.
Phase 3
204
Gdynia, Lodz, Lublin, Pabianice, Piaseczno, Warsaw
2024-08-27
Active, closed
Zenas BioPharma (USA), LLC
Phase 2
93
Bydgoszcz, Katowice, Lublin, Zabrze
2024-08-26
Recruiting
Colorado Prevention Center
Phase 3
2,600
Lublin, Oświęcim, Krakow, Lodz, Tychy
2024-08-20
Recruiting
EFS of the DUO System for Tricuspid Regurgitation
NCT05913908Tricuspid Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease, Heart Valve Diseases
CroiValve Limited
Not applicable
15
Poznan, Warsaw, Katowice, Lublin
2024-08-13
Recruiting
AstraZeneca
Phase 3
620
Bialystok, Katowice, Krakow, Lublin, Warsaw, Wroclaw
2024-08-12
Recruiting
AstraZeneca
Phase 3
1,018
Gdansk, Gliwice, Katowice, Krakow, Lublin, Warsaw, Wroclaw
2024-08-07
Recruiting
AstraZeneca
Phase 3
788
Biała Podlaska, Koszalin, Lodz, Lublin, Poznan, Radom, Warsaw
2024-08-01
Active, closed
Novartis Pharmaceuticals
Phase 3
146
Lublin, Warsaw, Krakow, Katowice, Bydgoszcz, Poznan, Rzeszów
2024-07-31
By invitation
Biohaven Therapeutics Ltd.
Phase 2
660
Poznan, Wroclaw, Lublin, Świdnik, Nowa Sól, Lodz, Warsaw, Gdansk
2024-07-30
Active, closed
Celldex Therapeutics
Phase 3
976
Częstochowa, Elblag, Gdansk, Grodzisk Mazowiecki, Katowice, Krakow, Lodz, Lublin
2024-07-19
Active, closed
Vor Biopharma
Phase 3
191
Poznan, Bydgoszcz, Krakow, Lublin, Nowa Sól, Warsaw, Gdansk, Katowice
2024-07-17
Active, closed
Merck Sharp & Dohme LLC
Phase 3
300
Lublin, Katowice, Kielce
2024-07-16
Active, closed
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
NCT06290128Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic
DrugRiliprubart
Sanofi
Phase 3
109
Krakow, Lublin, Rzeszów
2024-07-12
Recruiting
AbbVie
Phase 3
40
Cracow, Lublin, Warsaw, Sosnowiec, Lodz
2024-07-08
Active, closed
Novartis Pharmaceuticals
Phase 2
155
Krakow, Lublin
2024-07-02
Active, closed
Novartis Pharmaceuticals
Phase 3
162
Lublin, Warsaw
2024-06-28
Active, closed
Celgene
Phase 3
850
Skórzewo, Bydgoszcz, Krakow, Lublin, Warsaw, Katowice
2024-06-19
Recruiting
Merck Sharp & Dohme LLC
Phase 3
851
Bydgoszcz, Grudziądz, Gorlice, Krakow, Poznań, Lublin, Warsaw, Przemyśl
2024-06-10
Active, closed
Janssen Research & Development, LLC
Phase 1
108
Biała Podlaska, Gdansk, Katowice, Kielce, Lublin, Wroclaw
2024-06-07
Active, closed
Janssen Research & Development, LLC
Phase 2
333
Biała Podlaska, Brzozów, Gdynia, Kielce, Krakow, Lodz, Lublin
2024-05-30
Recruiting
Merck Sharp & Dohme LLC
Phase 3
348
Gorlice, Krakow, Lublin, Warsaw, Przemyśl, Olsztyn
2024-05-24
Active, closed
AbbVie
Phase 3
421
Wroclaw, Lublin, Gdansk
2024-05-19
Recruiting
NMD Pharma A/S
Phase 2
84
Katowice, Krakow, Lublin, Myślenice, Warsaw
2024-05-16
Active, closed
Sanofi
Phase 3
1,541
Krakow, Tarnów, Lublin, Lodz, Warsaw, Gdansk, Katowice
2024-05-08
Recruiting
W.L.Gore & Associates
Observational
2,000
Lublin
2024-05-07
Active, closed
A Study Evaluating APG777 in Atopic Dermatitis
NCT06395948Atopic Dermatitis
DrugAPG777
Apogee Therapeutics, Inc.
Phase 2
470
Wroclaw, Lublin, Warsaw, Gdansk, Katowice, Sosnowiec, Szczecin, Krakow
2024-04-29
Active, closed
Eli Lilly and Company
Phase 3
450
Kielce, Krakow, Lodz, Lublin, Piła, Rzeszów, Skierniewice, Tarnów
2024-04-26
Recruiting
Karyopharm Therapeutics Inc
Phase 2
58
Lublin, Skórzewo, Torun
2024-04-22
Recruiting
Janssen Research & Development, LLC
Phase 3
641
Bialystok, Bydgoszcz, Lublin, Przemyśl, Tarnów, Torun, Wieliszew, Wroclaw
2024-04-18
Active, closed
argenx
Phase 3
119
Bydgoszcz, Katowice, Krakow, Lublin, Wroclaw
2024-04-16
Active, closed
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
DrugTeriflunomide
Sanofi
Phase 3
2,500
Plewiska, Bydgoszcz, Lublin, Lodz, Warsaw, Glogow Mlp., Katowice, Zabrze
2024-04-16
Active, closed
Celldex Therapeutics
Phase 2
140
Krakow, Gdynia, Katowice, Lublin, Rzeszów, Warsaw, Wroclaw
2024-04-12
Active, closed
Janssen Research & Development, LLC
Phase 3
272
Bialystok, Bydgoszcz, Krakow, Lublin, Przemyśl, Tarnów, Torun, Wieliszew
2024-04-09
Active, closed
Amgen
Phase 3
434
Krakow, Wroclaw, Lublin, Warsaw, Wołomin, Malbork, Bydgoszcz, Katowice
2024-04-08
Recruiting
Merck Sharp & Dohme LLC
Phase 3
780
Poznan, Krakow, Lublin, Warsaw, Przemyśl, Bialystok, Gdansk, Prabuty
2024-04-03
Recruiting
Copernicus Memorial Hospital
Not applicable
165
Lublin, Lodz
2024-04-01
Active, closed
Takeda
Phase 2
213
Wroclaw, Torun, Bydgoszcz, Warsaw, Szczecin, Lodz, Lublin, Rzeszów
2024-03-29
Active, closed
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
NCT06291376Immunoglobulin A Nephropathy, IgAN
DrugRavulizumab
Alexion Pharmaceuticals, Inc.
Phase 3
584
Bialystok, Krakow, Lodz, Lublin, Olsztyn, Poznan, Szczecin, Warsaw
2024-03-29
Active, closed
AstraZeneca
Phase 3
2,554
Chrzanów, Gdynia, Krakow, Lodz, Lublin, Olsztyn, Poznan, Rzeszów
2024-03-29
Active, closed
Gilead Sciences
Phase 2
228
Bydgoszcz, Katowice, Krakow, Ksawerów, Lublin, Mazowieckie, Poznan, Rzeszów
2024-03-27
Active, closed
AbbVie
Phase 2
156
Torun, Wroclaw, Lublin, Chojnice, Tychy, Szczecin, Ksawerów
2024-03-23
Active, closed
Biohaven Therapeutics Ltd.
Phase 2/3
390
Poznan, Lublin, Świdnik, Nowa Sól, Lodz, Warsaw, Gdansk, Katowice
2024-03-14
Recruiting
Takeda
Phase 2
268
Torun, Wroclaw, Warsaw, Szczecin, Bydgoszcz, Lodz, Lublin, Poznan
2024-03-05
Active, closed
AstraZeneca
Phase 3
594
Bielsko-Biala, Gdansk, Katowice, Krakow, Lublin, Słupsk, Warsaw
2024-03-04
Recruiting
medac GmbH
Phase 3
277
Częstochowa, Gdansk, Katowice, Lodz, Lublin, Mikołów, Poznan, Szczecin
2024-02-27
Active, closed
Dianthus Therapeutics
Phase 2
65
Bydgoszcz, Katowice, Krakow, Lublin, Warsaw
2024-02-23
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
762
Gdansk, Lodz, Lublin, Poznan
2024-02-21
Active, closed
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
NCT06117774Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
DrugTarlatamab
Amgen
Phase 3
404
Bialystok, Bystra, Gdansk, Lublin, Poznan, Prabuty, Przemyśl, Warsaw
2024-02-20
Active, closed
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
NCT05853575Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung
DrugAdagrasib
Mirati Therapeutics Inc.
Phase 2
200
Krakow, Gdynia, Lublin
2024-02-01
Active, closed
Incyte Corporation
Phase 3
617
Lublin, Ostrowiec Świętokrzyski, Rzeszów, Warsaw, Wroclaw
2024-01-30
Active, closed
Janssen Research & Development, LLC
Phase 3
838
Biała Podlaska, Brzozów, Kielce, Lublin, Szczecin, Wroclaw
2024-01-22
Recruiting
Colorado Prevention Center
Phase 3
5,200
Katowice, Krakow, Lodz, Lublin, Oświęcim, Tychy
2024-01-17
Recruiting
Regeneron Pharmaceuticals
Phase 3
580
Bydgoszcz, Wałbrzych, Wroclaw, Lublin, Krakow, Gdansk, Poznan, Skorzewo
2023-12-28
Recruiting
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
NCT06059638Hypertension, Hypertension, Systolic, Hypertension, Essential
Orchestra BioMed, Inc
Not applicable
316
Katowice, Krakow, Lodz, Lublin, Poznan, Szczecin, Warsaw, Wroclaw
2023-12-27
Active, closed
Bristol-Myers Squibb
Phase 3
190
Lublin, Olsztyn
2023-12-21
Active, closed
REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)
NCT05973773Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
DrugZipalertinib
Taiho Oncology, Inc.
Phase 3
285
Pozna?, Lublin, Lodz
2023-12-18
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Krakow, Lublin, Warsaw, Gdansk, Słupsk, Gliwice, Katowice, Olsztyn
2023-12-13
Active, closed
Sanofi
Phase 3
1,655
Plewiska, Bydgoszcz, Krakow, Lublin, Lodz, Warsaw, Rzeszów, Katowice
2023-12-13
Recruiting
Regeneron Pharmaceuticals
Phase 3
904
Krakow, Wroclaw, Poznan, Skorzewo, Bydgoszcz, Gdansk, Lublin, Warsaw
2023-12-13
Recruiting
Regeneron Pharmaceuticals
Phase 3
822
Wałbrzych, Wroclaw, Krakow, Gdansk, Skorzewo, Katowice, Lodz, Lublin
2023-12-12
Active, closed
Hoffmann-La Roche
Phase 3
1,050
?ód?, Bydgoszcz, Gdynia, Gliwice, Kielce, Konin, Koszalin, Lublin
2023-12-11
Active, closed
LimmaTech Biologics AG
Phase 1/2
251
Skórzewo, Bydgoszcz, Katowice, Lublin, Warsaw
2023-12-06
Active, closed
Gilead Sciences
Phase 2
176
Krakow, Lublin, Poznan, Rzeszów, Sopot, Warsaw, Wroclaw
2023-12-05
Active, closed
AnaptysBio, Inc.
Phase 2
132
Bydgoszcz, Częstochowa, Elblag, Katowice, Krakow, Lodz, Lublin, Poznan
2023-12-04
Active, closed
AstraZeneca
Phase 3
760
Bydgoszcz, Krakow, Lublin, Przemyśl, Warsaw
2023-12-04
Active, closed
argenx
Observational
413
Bydgoszcz, Katowice, Krakow, Lublin, Warsaw
2023-11-29
Active, closed
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
NCT06016738Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
DrugsPalazestrant·Exemestane·Anastrozole·Letrozole
Olema Pharmaceuticals, Inc.
Phase 3
510
Lublin, Lodz, Otwock, Brzozów, Rzeszów, Gdynia, Gdansk, Krakow
2023-11-16
Recruiting
Amgen
Phase 3
750
Bialystok, Bystra, Gdynia, Gliwice, Krakow, Lodz, Lublin, Poznan
2023-11-16
Active, closed
Regeneron Pharmaceuticals
Phase 3
733
Krakow, Skorzewo, Bydgoszcz, Gdansk, Katowice, Lodz, Lublin, Warsaw
2023-11-14
Active, closed
medac GmbH
Phase 2
49
Wroclaw, Lublin, Poznan
2023-11-13
Active, closed
BeOne Medicines
Phase 3
652
Lodz, Lublin, Poznan, Warsaw, Wroclaw
2023-11-11
Active, closed
AstraZeneca
Phase 3
895
Lublin, Poznan, Przemyśl, Radom, Warsaw
2023-10-24
Active, closed
AskBio Inc
Phase 2
150
Chrzanów, Lublin
2023-10-20
Active, closed
Celgene
Phase 3
79
Lublin, Warsaw, Gliwice, Gdansk, Poznan
2023-10-16
Active, closed
Ipsen
Phase 3
759
Bydgoszcz, Gdynia, Katowice, Krakow, Lublin, Oświęcim
2023-10-12
Active, closed
Merck Sharp & Dohme LLC
Phase 3
14,550
Poznan, Bydgoszcz, Torun, Chrzanów, Krakow, Tarnów, Legnica, Lublin
2023-10-09
Active, closed
Ipsen
Phase 3
751
Bydgoszcz, Gdynia, Katowice, Krakow, Lublin, Oświęcim
2023-09-29
Recruiting
Regeneron Pharmaceuticals
Phase 3
410
Gdansk, Bydgoszcz, Katowice, Lublin, Lodz
2023-09-18
Active, closed
Bristol-Myers Squibb
Phase 3
774
Krakow, Warsaw, Bydgoszcz, Lublin, Poznan, Wroclaw
2023-09-11
Recruiting
Ipsen
Phase 3
276
Elblag, Katowice, Krakow, Lodz, Lublin, Małogoskie, Rzeszów, Sosnowiec
2023-08-31
Active, closed
Teva Branded Pharmaceutical Products R&D LLC
Phase 3
2,772
Bialystok, Bydgoszcz, Elblag, Gdansk, Krakow, Lodz, Lublin, Maków Podhalański
2023-08-30
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
500
Lublin, Lodz, Sopot, Katowice, Bydgoszcz, Siemianowice Śląskie, Ścinawa
2023-08-28
Recruiting
Hoth Therapeutics, Inc.
Phase 2
152
Krakow, Lublin
2023-07-19
Recruiting
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
NCT05727176Advanced Cholangiocarcinoma, FGFR2 Fusions, Gene Rearrangement
DrugFutibatinib
Taiho Oncology, Inc.
Phase 2
120
Koszalin, Lublin, Otwock, Warsaw
2023-07-05
Active, closed
Swedish Orphan Biovitrum
Observational
165
Bialystok, Bydgoszcz, Gdansk, Krakow, Lodz, Lublin, Warsaw
2023-06-26
Recruiting
Innate Pharma
Phase 2
70
Bialystok, Krąków, Lublin, Poznan, Prabuty, Warsaw
2023-06-23
Active, closed
Bristol-Myers Squibb
Phase 3
1,230
Bydgoszcz, Gdansk, Gliwice, Katowice, Lublin, Warsaw, Lodz
2023-06-22
Recruiting
GlaxoSmithKline
Phase 1/2
123
Gdansk, Lublin
2023-06-14
Recruiting
H. Lundbeck A/S
Phase 3
315
Krakow, Oświęcim, Lublin, Warsaw
2023-06-08
By invitation
AbbVie
Phase 3
650
Poznan, Bydgoszcz, Krakow, Lublin, Warsaw, Wroclaw
2023-06-05
Recruiting
Medical University of Lublin
Phase 2
300
Lublin
2023-05-31
Active, closed
Takeda
Observational
50
Wroclaw, Poznan, Bydgoszcz, Krakow, Lublin, Warsaw, Rzeszów, Bystra
2023-05-22
Active, closed
Janssen Research & Development, LLC
Phase 1/2
71
Lublin, Poznan, Warsaw
2023-05-18
Recruiting
Xenon Pharmaceuticals Inc.
Phase 3
360
Gdansk, Lublin, Nowa Sól, Warsaw
2023-05-09
Active, closed
Gilead Sciences
Phase 3
654
Gdansk, Krakow, Lodz, Lublin, Warsaw
2023-05-08
Recruiting
AbbVie
Phase 3
450
Poznan, Bydgoszcz, Krakow, Lublin, Warsaw, Wroclaw
2023-05-01
By invitation
An Open-label Study of XEN1101 in Epilepsy
NCT05718817Focal Epilepsy, Tonic-Clonic Seizures
DrugAzetukalner
Xenon Pharmaceuticals Inc.
Phase 3
880
Bydgoszcz, Gdansk, Lublin, Nowa Sól, Warsaw
2023-04-25
Active, closed
Alfasigma S.p.A.
Phase 3
495
Bialystok, Elblag, Katowice, Lubin, Lublin, Nowa Sól, Olsztyn, Opole
2023-04-05
Active, closed
Bayer
Phase 3
985
Bydgoszcz, Kielce, Krakow, Lublin, Warsaw, Wroclaw
2023-04-03
Active, closed
Sanofi
Phase 2
999
Lublin, Lodz, Warsaw, Gdansk, Chorzów, Katowice
2023-04-03
Recruiting
AstraZeneca
Phase 3
4,300
Bialystok, Grudziądz, Koszalin, Lodz, Lublin, Opole, Poznan, Racibórz
2023-03-31
Active, closed
Janssen Research & Development, LLC
Phase 3
614
Gdansk, Katowice, Kielce, Lublin
2023-03-29
Active, closed
Janssen Research & Development, LLC
Phase 3
1,135
Bialystok, Bydgoszcz, Lublin, Piotrkow Trybunalski, Poznan, Słupsk, Warsaw, Wroclaw
2023-03-23
Active, closed
Merck Sharp & Dohme LLC
Phase 3
300
Lublin, Warsaw, Gdansk, Katowice, Olsztyn, Kielce
2023-03-16
Active, closed
Novo Nordisk A/S
Phase 3
7,101
Ruda Śląska, Dąbrówka, Bygdoszcz, Chrzanów, Krakow, Wroclaw, Lublin, Poniatowa
2023-03-01
Recruiting
Xenon Pharmaceuticals Inc.
Phase 3
160
Bydgoszcz, Gdansk, Katowice, Lublin, Nowa Sól
2023-02-14
Active, closed
A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A
NCT05685238Haemophilia A, Haemophilia A With Inhibitors
Novo Nordisk A/S
Phase 3
451
Poznan, Wroclaw, Warsaw, Krakow, Lublin
2023-02-13
Recruiting
Tampere University
Not applicable
12,000
Bialystok, Katowice, Krakow, Lublin, Toruniak, Warsaw
2023-02-01
Active, closed
Areteia Therapeutics
Phase 3
600
Będzin, Bialystok, Gdansk, Giżycko, Katowice, Krakow, Lodz, Lublin
2023-01-30
Active, closed
Silence Therapeutics plc
Phase 1/2
69
Gdansk, Katowice, Lublin
2023-01-26
Active, closed
ABTECT - Maintenance
NCT05535946Ulcerative Colitis
DrugObefazimod
Abivax S.A.
Phase 3
1,116
Bialystok, Bydgoszcz, Kalisz, Kielce, Knurów, Krakow, Lodz, Lublin
2023-01-16
Active, closed
Bristol-Myers Squibb
Phase 3
513
Poznan, Krakow, Lublin, Warsaw, Chorzów, Elblag, Szczecin, Wroclaw
2023-01-12
Active, closed
Bristol-Myers Squibb
Phase 3
516
Poznan, Bydgoszcz, Krakow, Nadarzyn, Warsaw, Katowice, Bialystok, Lublin
2023-01-12
Active, closed
Daiichi Sankyo
Phase 3
1,170
Bialystok, Lodz, Lublin, Poznan, Warsaw
2023-01-11
Recruiting
Medical University of Bialystok
Not applicable
366
Bialystok, Bydgoszcz, Lodz, Lublin
2023-01-10
Recruiting
Xanthohumol as an Adjuvant in the Treatment of Septic Shock
NCT06225258Septic Shock, Pneumonia, ARDS
Medical University of Lublin
Phase 2
50
Lublin
2023-01-09
Active, closed
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
NCT05024773Bladder Carcinoma in Situ (CIS)
Fidia Farmaceutici s.p.a.
Phase 3
130
Przemyśl, Warsaw, Lublin
2022-12-29
Active, closed
Incyte Corporation
Phase 3
82
Bydgoszcz, Gdansk, Gdynia, Lublin, Olsztyn, Skórzewo, Warsaw, Wroclaw
2022-12-23
Recruiting
Medical University of Lublin
Observational
125
Lublin
2022-12-20
Active, closed
Ionis Pharmaceuticals, Inc.
Phase 3
885
Gdansk, Józefów, Katowice, Lodz, Lublin, Poznan, Tarnów, Warsaw
2022-12-13
Active, closed
Viatris Innovation GmbH
Phase 3
470
Bialystok, Częstochowa, Katowice, Krakow, Lublin, Wroclaw
2022-12-13
Active, closed
Janssen Research & Development, LLC
Phase 1/2
57
Gdansk, Lublin, Warsaw
2022-12-13
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 3
260
Bydgoszcz, Katowice, Krakow, Lublin, Poznan
2022-11-21
Active, closed
Novo Nordisk A/S
Phase 3
3,400
Bydgoszcz, Krakow, Legnica, Lublin, Warsaw, Bialystok, Gdansk, Katowice
2022-11-01
Recruiting
Janssen Research & Development, LLC
Phase 3
1,590
Biała Podlaska, Brzozów, Bydgoszcz, Katowice, Kielce, Lodz, Lublin, Poznan
2022-10-25
Active, closed
Almirall, S.A.
Phase 4
447
Lublin, Rzeszów, Warsaw, Wroclaw
2022-10-24
Active, closed
AbbVie
Phase 1
283
Opole, Wroclaw, Lublin, Gdansk
2022-10-20
Active, closed
GlaxoSmithKline
Phase 2
351
Lublin, Prabuty, Siedlce
2022-10-14
Active, closed
Janssen Research & Development, LLC
Phase 3
864
Brzozów, Gdansk, Katowice, Kielce, Krakow, Lublin, Olsztyn, Szczecin
2022-10-13
Active, closed
Eli Lilly and Company
Phase 3
15,374
Bialystok, Bydgoszcz, Chorzów, Elblag, Gdansk, Krakow, Lodz, Lublin
2022-10-11
Recruiting
Janssen Research & Development, LLC
Phase 2/3
201
Chorzów, Krakow, Lublin, Poznan
2022-09-23
Active, closed
Janssen Research & Development, LLC
Phase 2
577
Bydgoszcz, Krakow, Lodz, Lublin, Nowy Targ, Olsztyn, Poznan, Rzeszów
2022-09-19
Active, closed
Janssen Research & Development, LLC
Phase 3
418
Bialystok, Bydgoszcz, Chojnice, Krakow, Lublin, Poznan, Rzeszów, Szczecin
2022-09-13
Active, closed
AstraZeneca
Phase 3
607
Bydgoszcz, Gdansk, Katowice, Krakow, Lódz, Lublin
2022-09-12
Active, closed
Study of Sonrotoclax (BGB-11417) Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma
NCT05471843Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma (MCL), Relapsed Mantle Cell Lymphoma
DrugSonrotoclax
BeOne Medicines
Phase 1/2
125
Gdansk, Krakow, Lublin
2022-09-05
Active, closed
Medical University of Lublin
Not applicable
40
Lublin
2022-09-01
Active, closed
GlaxoSmithKline
Phase 1/2
14
Lublin
2022-08-31
Active, closed
Biogen
Phase 2
416
Bialystok, Bydgoszcz, Katowice, Krakow, Lodz, Lublin, Sopot, Warsaw
2022-08-24
Active, closed
Sanofi
Phase 2/3
1,856
Torun, Krakow, Tarnów, Wroclaw, Lublin, Lodz, Warsaw, Rzeszów
2022-08-22
Recruiting
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05254743Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
DrugsPirtobrutinib·Ibrutinib
Loxo Oncology, Inc.
Phase 3
737
Biała Podlaska, Bydgoszcz, Gdansk, Katowice, Krakow, Lublin, Skórzewo, Wroclaw
2022-07-22
Active, closed
Janssen Research & Development, LLC
Phase 2
703
Bydgoszcz, Krakow, Lodz, Lublin, Olsztyn, Poznan, Rzeszów, Sopot
2022-07-22
Active, closed
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
NCT05458297Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
DrugsZilovertamab vedotin·Nemtabrutinib
Merck Sharp & Dohme LLC
Phase 2
189
Krakow, Lublin, Warsaw, Olsztyn, Lodz, Kielce
2022-07-21
Active, closed
Daiichi Sankyo
Phase 3
586
Bialystok, Lublin, Poznan
2022-07-08
Active, closed
Sun Pharmaceutical Industries Limited
Phase 3
529
Bialystok, Krakow, Lublin, Nadarzyn, Olsztyn, Poznan, Torun, Warsaw
2022-06-30
Active, closed
Cogent Biosciences, Inc.
Phase 2
237
Gdansk, Lublin
2022-06-27
Active, closed
Sanofi
Phase 3
531
Krakow, Wroclaw, Lublin
2022-06-23
Active, closed
THIO Sequenced With Cemiplimab in Advanced NSCLC
NCT05208944Carcinoma, Non-Small-Cell Lung
DrugsThiotepa·Cemiplimab
Maia Biotechnology
Phase 2
227
Oświęcim, Bydgoszcz, Krakow, Lodz, Lublin, Poznan, Rzeszów, Skorzewo
2022-06-08
Recruiting
Actelion
Phase 3
280
Bialystok, Bydgoszcz, Katowice, Lodz, Lublin, Szczecin, Wroclaw
2022-05-04
Recruiting
MicuRx
Phase 3
865
Lublin, Warsaw
2022-05-03
Active, closed
Hoffmann-La Roche
Phase 3
1,300
Bydgoszcz, Gda?sk, Katowice, Krakow, Lodz, Lublin, Olsztyn, Plewiska
2022-05-03
Active, closed
Eli Lilly and Company
Phase 3
925
Lublin, Opole, Gdynia, Lodz, Piotrkow Trybunalski
2022-04-14
Recruiting
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
NCT05131022Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL)
DrugBexobrutideg
Nurix Therapeutics, Inc.
Phase 1
572
Skórzewo, Krakow, Wroclaw, Warsaw, Katowice, Lublin
2022-04-13
Active, closed
Novo Nordisk A/S
Phase 3
153
Wroclaw, Gdansk, Lublin, Warsaw
2022-03-24
By invitation
Optimal PeriproCeduraL AnticOagulation in Structural Transseptal Interventions
NCT05305612Mitral Regurgitation, Atrial Fibrillation, Anticoagulation
National Institute of Cardiology, Warsaw, Poland
Phase 4
410
Gdansk, Katowice, Lublin, Poznan, Warsaw
2022-03-13
Recruiting
Takeda
Observational
70
Wroclaw, Poznan, Krakow, Lublin, Tomaszow Mazowiecki, Warsaw, Gdansk, Katowice
2022-03-08
Active, closed
Daiichi Sankyo
Phase 3
740
Lodz, Gdynia, Szczecin, Bialystok, Lublin
2022-03-04
Recruiting
Pfizer
Phase 3
640
Poznan, Krakow, Wroclaw, Lublin, Warsaw, Katowice
2022-02-28
By invitation
UCB Biopharma SRL
Phase 3
300
Bydgoszcz, Gdansk, Krakow, Lublin, Nowa Sól, Świdnik
2022-02-03
Active, closed
Merck Sharp & Dohme LLC
Phase 3
280
Poznan, Lublin, Siedlce, Warsaw, Bialystok, Gliwice, Kielce
2022-02-03
Active, closed
Janssen Research & Development, LLC
Phase 3
350
Bialystok, Bydgoszcz, Chojnice, Chrzanów, Knurów, Krakow, Lodz, Lublin
2022-01-19
Recruiting
Merck Sharp & Dohme LLC
Phase 2/3
290
Krakow, Wałbrzych, Wroclaw, Lublin, Warsaw, Gdynia, Słupsk, Katowice
2022-01-14
Active, closed
Immunic AG
Phase 3
1,100
Katowice, Lublin, Plewiska, Poznan, Warsaw, Zabrze
2022-01-12
Active, closed
Noema Pharma AG
Phase 2/3
166
Dąbrowa Górnicza, Krakow, Lodz, Lublin, Wroclaw
2022-01-11
Active, closed
Novartis Pharmaceuticals
Phase 3
1,000
Wroclaw, Bydgoszcz, Kielce, Lodz, Lublin, Piotrkow Trybunalski, Poznan, Rzeszów
2021-12-16
Active, closed
GlaxoSmithKline
Phase 2
360
Gdansk, Krakow, Lublin, Mysłowice, Żychlin, Łańcut
2021-12-14
Active, closed
Novartis Pharmaceuticals
Phase 3
1,007
Plewiska, Bialystok, Glogow Wielkopolski, Katowice, Lublin, Wroclaw, Zabrze
2021-12-13
Recruiting
UCB Biopharma SRL
Phase 3
350
Bydgoszcz, Gdansk, Krakow, Lublin, Nowa Sól, Poznan, Świdnik
2021-12-07
Active, closed
Abivax S.A.
Phase 2
203
Krakow, Lublin, Oświęcim, Piotrkow Trybunalski, Poznan, Tarnów, Warsaw, Wroclaw
2021-12-03
Recruiting
H. Lundbeck A/S
Phase 3
600
Krakow, Oświęcim, Lublin, Warsaw
2021-12-01
Active, closed
Immunic AG
Phase 3
1,121
Lublin
2021-11-18
Active, closed
Sirolimus-coated Balloon Versus Drug-eluting Stent in Native Coronary Vessels - TRANSFORM II
NCT04893291Coronary Artery Disease, Coronary Artery Stenosis
Fondazione Ricerca e Innovazione Cardiovascolare ETS
Not applicable
1,820
Lublin, Poznan
2021-11-16
Recruiting
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
NCT04996875Advanced Systemic Mastocytosis (AdvSM), SM With an Associated Hematologic Neoplasm (SM-AHN), Mast Cell Leukemia (MCL), Aggressive Systemic Mastocytosis (ASM)
DrugBezuclastinib
Cogent Biosciences, Inc.
Phase 2
140
Lublin
2021-11-09
Active, closed
AstraZeneca
Phase 3
927
Bialystok, Biała Podlaska, Bydgoszcz, Koszalin, Lublin, Rzeszów, Warsaw
2021-10-25
Active, closed
Janssen Research & Development, LLC
Phase 3
587
Gdansk, Katowice, Kielce, Lublin, Warsaw, Wałbrzych, Wroclaw
2021-10-14
Recruiting
ContraBand™: Safety & Feasibility Study (RM-20-01)
NCT05230745Heart Failure, Left Sided
Restore Medical Ltd
Not applicable
55
Krakow, Lublin
2021-09-28
Active, closed
Loxo Oncology, Inc.
Phase 3
282
Iwaszkiewicza 5, Lublin, Gdansk, Skorzewo, Biała Podlaska, Bydgoszcz, Katowice, Krakow
2021-09-23
Active, closed
Loxo Oncology, Inc.
Phase 3
600
Gdynia, Katowice, Krakow, Lodz, Lublin, Torun, Warsaw
2021-09-20
Active, closed
Janssen Research & Development, LLC
Phase 4
411
Bialystok, Bydgoszcz, Bytom, Elblag, Krakow, Lodz, Lublin, Nadarzyn
2021-08-30
Active, closed
Hoffmann-La Roche
Phase 3
4,170
Bydgoszcz, Gdynia, Gliwice, Grudziądz, Krakow, Lodz, Lublin, Poznan
2021-08-27
Active, closed
Janssen Research & Development, LLC
Phase 3
743
Gdansk, Gliwice, Lublin, Poznan, Warsaw, Wroclaw
2021-08-19
By invitation
UCB Biopharma SRL
Phase 3
760
Bialystok, Bydgoszcz, Katowice, Krakow, Lublin, Poznan, Warsaw, Wroclaw
2021-07-27
Recruiting
Janssen Research & Development, LLC
Phase 3
199
Bydgoszcz, Katowice, Krakow, Lublin, Warsaw
2021-07-15
Active, closed
VectivBio AG
Phase 3
158
Bydgoszcz, Gdansk, Lodz, Lublin, Skawina
2021-07-13
Active, closed
Bristol-Myers Squibb
Phase 3
670
Dąbrówka, Krakow, Nowy Targ, Wroclaw, Lublin, Świdnik, Nadarzyn, Warsaw
2021-07-13
Recruiting
H. Lundbeck A/S
Phase 3
285
Krakow, Oświęcim, Lublin, Warsaw
2021-06-30
Active, closed
Janssen Research & Development, LLC
Phase 3
1,054
Bialystok, Bydgoszcz, Elblag, Gdynia, Krakow, Lublin, Nadarzyn, Nowa Sól
2021-06-17
Active, closed
AstraZeneca
Phase 3
367
Katowice, Kościan, Krakow, Lodz, Lublin, Nowa Sól, Ustroń, Warsaw
2021-06-08
Active, closed
Biogen
Phase 3
548
Bialystok, Bydgoszcz, Bytom, Krakow, Lublin, Malbork, Nowa Sól, Poznan
2021-05-25
Active, closed
Hoffmann-La Roche
Phase 2
586
?ód?, Bydgoszcz, Gda?sk, Krakow, Lublin, Rzeszów, Warsaw
2021-05-05
Active, closed
Incyte Corporation
Phase 3
654
Brzozów, Katowice, Krakow, Lodz, Lublin, Tomaszów Mazowiecki, Warsaw, Wroclaw
2021-04-15
Active, closed
Loxo Oncology, Inc.
Phase 3
500
Lublin, Gdansk, Krakow, Lodz, Skorzewo, Wroclaw
2021-04-08
Active, closed
Hoffmann-La Roche
Phase 3
746
?ory, Bydgoszcz, Katowice, Krosno, Lodz, Lublin, Warsaw, Zabrze
2021-03-17
Active, closed
Karyopharm Therapeutics Inc
Phase 3
353
Skórzewo, Torun, Wroclaw, Lublin, Brzozów, Gdansk, Katowice, Wałbrzych
2021-03-11
Active, closed
Loxo Oncology, Inc.
Phase 3
238
Iwaszkiewicza 5, Lublin, Gdansk, Gdynia, Brzozów, Bydgoszcz, Katowice, Krakow
2021-03-09
Active, closed
Hoffmann-La Roche
Phase 3
270
Gdansk, Lublin, Olsztyn, Warsaw, Wroc?aw
2021-02-23
Active, closed
Mirati Therapeutics Inc.
Phase 3
453
Lodz, Lublin, Otwock, Rzeszów, Skorzewo, Torun, Warsaw
2021-02-23
Active, closed
Anthos Therapeutics, Inc.
Phase 2
1,287
Gdynia, Chrzanów, Krakow, Wroclaw, Żarów, Lublin, Zamość, Płock
2021-02-02
Active, closed
AstraZeneca
Phase 1
155
Gdansk, Lodz, Lublin, Warsaw
2021-02-02
Active, closed
AstraZeneca
Phase 3
1,371
Gdynia, Konin, Koszalin, Lodz, Lublin, Olsztyn, Poznan
2021-01-28
Active, closed
AstraZeneca
Phase 1/2
245
Bydgoszcz, Koszalin, Lodz, Lublin
2020-12-28
Active, closed
Daiichi Sankyo
Phase 3
605
Bialystok, Gdynia, Lublin, Olsztyn, Poznan, Prabuty, Słupsk, Warsaw
2020-12-21
Active, closed
Hoffmann-La Roche
Phase 3
769
Bydgoszcz, Gdansk, Katowice, Krakow, Lodz, Lublin, Oświęcim, Plewiska
2020-12-03
Recruiting
Mirati Therapeutics Inc.
Phase 2/3
626
Gdansk, Kielce, Krakow, Lublin, Olsztyn, Otwock, Poznan, Skorzewo
2020-12-02
Active, closed
Hoffmann-La Roche
Phase 3
864
Bydgoszcz, Gdansk, Katowice, Lodz, Lublin, Późna, Rzeszów, Szczecin
2020-11-26
Recruiting
Resorbable Magnesium Scaffolds Registry
NCT04679740Coronary Artery Disease
Biotronik AG
Observational
1,106
Lublin
2020-11-18
Active, closed
Bayer
Phase 4
654
Krakow, Wroclaw, Lublin, Warsaw, Koszalin
2020-11-09
Active, closed
Bayer
Phase 3
402
Lodz, Lublin, Otwock, Siedlce, Warsaw
2020-10-20
Active, closed
Acerta Pharma BV
Phase 3
611
Gdansk, Krakow, Lodz, Lublin, Warsaw, Wroclaw
2020-10-08
Active, closed
Hoffmann-La Roche
Phase 3
210
Bydgoszcz, Gdansk, Lublin, Skórzewo, Warsaw
2020-10-08
Active, closed
Hoffmann-La Roche
Phase 3
190
Bydgoszcz, Gda?sk, Lublin, Skórzewo, Warsaw
2020-09-30
Active, closed
Janssen Research & Development, LLC
Phase 3
696
Bydgoszcz, Gdynia, Konin, Krakow, Lodz, Lublin, Siedlce, Warsaw
2020-09-23
Active, closed
argenx
Phase 2
229
Krakow, Lodz, Lublin, Warsaw
2020-09-18
Active, closed
AbbVie
Phase 3
531
Bydgoszcz, Lublin, Warsaw, Gdansk, Katowice, Lodz
2020-09-10
Active, closed
AbbVie
Phase 3
330
Piła, Poznan, Krakow, Lublin, Warsaw, Gdansk, Katowice, Lodz
2020-08-31
Active, closed
Hoffmann-La Roche
Phase 3
271
Lublin, Poznan, Warsaw, Wroclaw
2020-08-10
Active, closed
AstraZeneca
Phase 3
185
Bialystok, Grzepnica, Lublin, Olsztyn, Poznan
2020-08-04
Active, closed
Sun Pharmaceutical Industries Limited
Phase 3
296
Bialystok, Lublin, Poznan, Warsaw
2020-07-01
Active, closed
Eli Lilly and Company
Phase 3
996
Poznan, Bydgoszcz, Krakow, Wadowice, Swidnica, Wroclaw, Lublin, Zamość
2020-06-22
Active, closed
Eli Lilly and Company
Phase 3
1,736
Poznan, Bydgoszcz, Krakow, Ścinawa, Wroclaw, Lublin, Warsaw, Warsawawa
2020-06-19
Active, closed
GlaxoSmithKline
Phase 1/2
106
Katowice, Lodz, Lublin
2020-06-08
Recruiting
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
NCT04256317Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm, Chronic Myelomonocytic Leukemia
DrugsVenclexta·Azacitidine·Venetoclax
Taiho Oncology, Inc.
Phase 2/3
316
Lublin, Lodz, Gdynia
2020-05-21
Active, closed
GlaxoSmithKline
Phase 3
494
Chorzów, Krakow, Lodz, Lublin, Nowy Sącz, Poznan, Warsaw
2020-05-07
Active, closed
AstraZeneca
Phase 3
805
Gdansk, Lodz, Lublin, Olsztyn
2020-05-05
Active, closed
Amgen
Phase 3
145
Lublin, Poznan
2020-02-26
Active, closed
Sun Pharmaceutical Industries Limited
Phase 2/3
135
Bialystok, Katowice, Lodz, Lublin, Ostrowiec Świętokrzyski, Sosnowiec, Szczecin, Warsaw
2020-01-15
Active, closed
Sperm Selection Strategies and Male-Factor Phenotypes in ICSI
NCT07825584Assisted Reproductive Technology, Assisted Reproductive Technology Outcomes
Center for Reproductive Medicine Bocian
Observational
12,561
Poznan, Lublin, Warsaw, Rzeszów, Bialystok, Gdansk, Katowice, Szczecin
2020-01-02
Active, closed
GlaxoSmithKline
Phase 1
118
Lublin, Poznan
2019-12-18
Active, closed
Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors
NCT04082429Haemophilia A Without Inhibitors, Haemophilia B Without Inhibitors
DrugConcizumab
Novo Nordisk A/S
Phase 3
156
Poznan, Krakow, Warsaw, Lublin, Wroclaw
2019-11-13
Active, closed
Novo Nordisk A/S
Phase 3
134
Poznan, Krakow, Warsaw, Lublin, Wroclaw
2019-10-21
Active, closed
GlaxoSmithKline
Phase 1/2
208
Gdansk, Katowice, Lodz, Lublin
2019-10-07
Active, closed
Janssen Research & Development, LLC
Phase 2/3
1,064
Bialystok, Bydgoszcz, Krakow, Lublin, Oświęcim, Rzeszów, Sopot, Szczecin
2019-09-26
Active, closed
Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury
NCT03992404Lower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain Injury
DrugXeomin
Merz Pharmaceuticals GmbH
Phase 3
603
Katowice, Krakow, Lodz, Lublin, Warsaw, Wroclaw
2019-09-16
Recruiting
Medical University of Lublin
Observational
50
Lublin
2019-09-01
Recruiting
University Hospital Muenster
Phase 3
683
Bialystok, Bydgoszcz, Chorzów, Gdansk, Kielce, Krakow, Lodz, Lublin
2019-08-23
Active, closed
Hoffmann-La Roche
Phase 3
1,013
Bydgoszcz, Wroclaw, Lublin, Rzeszów, Rybnik, Bia?ystok, Gda?sk, Grodzisk Mazowiecki
2019-08-12
Recruiting
Bristol-Myers Squibb
Phase 2
1,500
Bydgoszcz, Olsztyn, Biała Podlaska, Gdansk, Krakow, Lodz, Lublin, Poznan
2019-08-09
Active, closed
Acerta Pharma BV
Phase 3
984
Brzozów, Bydgoszcz, Gdynia, Krakow, Lodz, Lublin, Wroclaw
2019-02-25
Active, closed
Immunic AG
Phase 2
210
Bydgoszcz, Lublin, Nadarzyn, Warsaw
2019-01-28
Active, closed
AstraZeneca
Phase 1/2
243
Gdansk, Krakow, Lublin, Opole, Rzeszów, Warsaw
2018-12-21
Active, closed
Novartis Pharmaceuticals
Phase 3
5,101
Warsaw, Bialystok, Gdynia, Gliwice, Grudziądz, Krakow, Lodz, Lublin
2018-12-07
Recruiting
Novartis Pharmaceuticals
Observational
700
Lublin
2018-09-25
Recruiting
Celgene
Phase 2/3
1,541
Gdansk, Lublin, Warsaw
2018-07-19
Active, closed
Eli Lilly and Company
Phase 3
1,058
Będzin, Bydgoszcz, Elblag, Katowice, Krakow, Lublin, Nowy Targ, Olsztyn
2018-07-18
Active, closed
A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.
NCT03504397Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsFolinic acid·Zolbetuximab·Fluorouracil·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
565
Lublin, Ostrołęka, Wieliszew, Brzozów, Warsaw
2018-06-21
Active, closed
pharmaand GmbH
Phase 3
1,097
Warsaw, Bialystok, Gdynia, Lublin, Poznan, Szczecin
2018-05-14
Active, closed
Corcept Therapeutics
Phase 2
125
Krakow, Lublin
2018-05-07
Active, closed
GlaxoSmithKline
Phase 2
237
Brzozów, Chorzów, Gdansk, Krakow, Lublin, Opole, Poznan
2018-05-03
Active, closed
Rna Diagnostics Inc.
Not applicable
801
Lublin
2018-04-26
Active, closed
Janssen Research & Development, LLC
Phase 3
211
Chorzów, Lodz, Lublin, Słupsk, Warsaw
2018-04-17
Rows per page Showing 1–500 of 523
1 2 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Polish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 29 October 2026. https://priyalifescience.com/clinical-trials-poland/city/lublin

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Poland and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,705 studies in total at the last sync on 28 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 523 of those studies with a site in Lublin.

How many clinical trials are recruiting in Lublin?

243 of the 523 studies on this page are recruiting new participants as of the 28 Oct 2026, 03:18 UTC sync. A further 8 have not yet opened recruitment, 260 are active but closed to new participants, and 12 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Lublin), 523 studies
PhaseStudiesRecruitingShare
Phase 332714362.5%
Phase 21024719.5%
Observational21144%
Not applicable20143.8%
Phase 2/317113.3%
Phase 1/21663.1%
Phase 11462.7%
Phase 4621.1%

Most active sponsors

Lead sponsors with the most studies (Lublin)
Lead sponsorStudiesRecruiting
AstraZeneca4425
Janssen Research & Development, LLC3613
Hoffmann-La Roche3013
Novo Nordisk A/S188
Eli Lilly and Company167
Merck Sharp & Dohme LLC168
Bristol-Myers Squibb158
Pfizer1513
AbbVie146
Sanofi145
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.